___

1. Messer T, Lammers G, Müller-Siecheneder F, Schmidt RF, Latifi S. Substance abuse in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry Res 2017; 253:338-350.

2. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54:313-321.

3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593-602. [CrossRef]

4. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511-2518. [CrossRef]

5. Tekin Uludag Y, Gulec G. Prevalence of substance use in patients diagnosed with schizophrenia. Noro Psikiyatr Ars 2016; 53:4-11.

6. Umut G, Arslan Delice M, Cansiz A, Can A, Kurt E, Evren C. Clinical characteristics of euthymic bipolar disorder patients comorbid with alcohol and drug use disorders and psychometric properties of the assessment tools. Bulletin of Clinical Psychopharmacology 2016; 26:48-57. [CrossRef]

7. Akkaya C, Altin M, Kora K, Karamustafalioglu N, Yasan A, Tomruk N, et al. Sociodemographic and clinical features of patients with bipolar i disorder in Turkey-HOME study. Bulletin of Clinical Psychopharmacology 2012; 22:31-42. [CrossRef]

8. Pacchiarotti I, Di Marzo S, Colom F, Sánchez-Moreno J, Vieta E. Bipolar disorder preceded by substance abuse: a different phenotype with not so poor outcome? World J Biol Psychiatry 2009; 10:209-216. [CrossRef]

9. Ostacher MJ, Perlis RH, Nierenberg AA, Calabrese J, Stange JP, Salloum I, et al; STEP-BD Investigators. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). Am J Psychiatry 2010; 167:289-297. [CrossRef]

10. Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2007; 2:29. [CrossRef]

11. Dalton EJ, Cate-Carter TD, Mundo E, Parikh SV, Kennedy JL. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 2003; 5:58-61. [CrossRef]

12. Altinbas K, Evren C. Pharmacotherapy options in comorbid bipolar disorder and alcohol-substance use disorders. Bulletin of Clinical Psychopharmacology 2013; 23:378-389. [CrossRef]

13. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37:171-178. [CrossRef]

14. Coles AS, Sasiadek J, George TP. Pharmacotherapies for co-occurring substance use and bipolar disorders: A systematic review. Bipolar Disord 2019; 21:595-610. [CrossRef]

15. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebocontrolled study. Arch Gen Psychiatry 2005; 62:37-45. [CrossRef]

16. Kemp DE, Gao K, Ganocy SJ, Elhaj O, Bilali SR, Conroy C, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapidcycling bipolar disorder and Co-occurring substance abuse or dependence. J Clin Psychiatry 2009; 70:113-121. [CrossRef]

17. Koethe D, Juelicher A, Nolden BM, Braunwarth WD, Klosterkötter J, Niklewski G, et al. Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: A doubleblind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res 2007; 31:1188-1194. [CrossRef]

18. Sylvia LG, Gold AK, Stange JP, Peckham AD, Deckersbach T, Calabrese JR, et al. A randomized, placebo-controlled proof-ofconcept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder. Am J Addict 2016; 25:94-98. [CrossRef]